checkAd

     444  0 Kommentare Idorsia initiates a multiple-dose efficacy and safety study with cenerimod for the treatment of systemic lupus erythematosus - Seite 4



    This announcement is distributed by West Corporation on behalf of West Corporation clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Idorsia Pharmaceuticals Ltd. via Globenewswire

    Lesen Sie auch

    --- End of Message ---

    Idorsia Pharmaceuticals Ltd.
    Hegenheimermattweg 91 Allschwil Switzerland

    ISIN: CH0363463438;


    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren
    Seite 4 von 4

    Verfasst von GlobeNewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Idorsia initiates a multiple-dose efficacy and safety study with cenerimod for the treatment of systemic lupus erythematosus - Seite 4 Idorsia Pharmaceuticals Ltd. / Idorsia initiates a multiple-dose efficacy and safety study with cenerimod for the treatment of systemic lupus erythematosus . Processed and transmitted by West Corporation. The issuer is solely responsible for the …

    Artikel zu den Werten

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer